文献速递淋巴瘤

TAp63/BCL2轴是慢性淋巴细胞白血病临床侵袭性的新机制

The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

本研究探讨p63转录因子TA亚型(TAp63)在慢性淋巴细胞白血病(CLL)病理生理中的作用。发现TAp63高表达与不良临床结局相关,包括疾病复发、至首次治疗时间缩短和总生存期缩短;TAp63与BCL2在蛋白和mRNA水平强相关,并通过CRISPR在MEC1 CLL细胞系中诱导TAp63下调导致BCL2表达下调;ChIP测序显示TAp63在BCL2基因位点(含CLL超级增强子区域)有显著结合;TAp63高表达使CLL细胞对BCL2抑制剂维奈克拉诱导的凋亡反应减弱。

要点

  • TAp63高表达与CLL不良临床结局相关,包括疾病复发、至首次治疗时间缩短和总生存期缩短。
  • TAp63与BCL2在蛋白和mRNA水平强相关,MEC1细胞系中TAp63下调导致BCL2表达下调。
  • TAp63高表达使CLL细胞对维奈克拉诱导的凋亡反应减弱。

核心结论

  • TAp63似乎是BCL2的正向调节因子,从而促成CLL临床侵袭性和治疗耐药所依赖的抗凋亡表型。

研究设计与样本

  • 研究探讨TAp63在CLL病理生理中的作用,包括临床结局关联分析、TAp63与BCL2的蛋白和mRNA相关性分析、MEC1 CLL细胞系中CRISPR诱导TAp63下调实验、染色质免疫沉淀测序(ChIP sequencing)分析TAp63在BCL2基因位点的结合谱,以及维奈克拉诱导凋亡的细胞反应评估。

主要发现

  • TAp63表达水平升高与不良临床结局相关,包括疾病复发、至首次治疗时间缩短和总生存期缩短。
  • TAp63与BCL2在蛋白和信使RNA(mRNA)水平均呈强相关。
  • 在MEC1 CLL细胞系中使用CRISPR系统诱导TAp63表达下调,导致BCL2表达下调。
  • ChIP测序显示TAp63在BCL2基因位点有显著结合谱,跨越既往在CLL中被表征为超级增强子的基因组区域。
  • 在主要参与免疫应答和DNA损伤过程的基因中鉴定出高置信度TAp63结合区域。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The TA-isoform of the p63 transcription factor (TAp63) has been reported to contribute to clinical aggressiveness in chronic lymphocytic leukemia (CLL) in a hitherto elusive way. Here, we sought to further understand and define the role of TAp63 in the pathophysiology of CLL. First, we found that elevated TAp63 expression levels are linked with adverse clinical outcomes, including disease relapse and shorter time-to-first treatment and overall survival. Next, prompted by the fact that TAp63 participates in an NF-κB/TAp63/BCL2 antiapoptotic axis in activated mature, normal B cells, we explored molecular links between TAp63 and BCL2 also in CLL. We documented a strong correlation at both the protein and the messenger RNA (mRNA) levels, alluding to the potential prosurvival role of TAp63. This claim was supported by inducible downregulation of TAp63 expression in the MEC1 CLL cell line using clustered regularly interspaced short palindromic repeats (CRISPR) system, which resulted in downregulation of BCL2 expression. Next, using chromatin immunoprecipitation (ChIP) sequencing, we examined whether BCL2 might constitute a transcriptional target of TAp63 and identified a significant binding profile of TAp63 in the BCL2 gene locus, across a genomic region previously characterized as a super enhancer in CLL. Moreover, we identified high-confidence TAp63 binding regions in genes mainly implicated in immune response and DNA-damage procedures. Finally, we found that upregulated TAp63 expression levels render CLL cells less responsive to apoptosis induction with the BCL2 inhibitor venetoclax. On these grounds, TAp63 appears to act as a positive modulator of BCL2, hence contributing to the antiapoptotic phenotype that underlies clinical aggressiveness and treatment resistance in CLL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Laidou S, Grigoriadis D, Papanikolaou S, et al. The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia. Blood Adv. 2022. PMID: 35235952. doi:10.1182/bloodadvances.2021006348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。